Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

ARZERRA

OFATUMUMAB

Standard Dose
100MG/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ARZERRA is listed in Drugs@FDA under application 125326 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient OFATUMUMAB Form and strength INJECTABLE; INJECTION - 100MG/5ML Sponsor NOVARTIS Submission history Latest submission status date: 2026-04-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview ARZERRA is listed in Drugs@FDA under application 125326 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient OFATUMUMAB Form and strength INJECTABLE; INJECTION - 100MG/5ML Sponsor NOVARTIS Submission history Latest submission status date: 2026-04-01 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.